Eton Pharmaceuticals (ETON) Net Income towards Common Stockholders (2019 - 2025)
Historic Net Income towards Common Stockholders for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to -$1.9 million.
- Eton Pharmaceuticals' Net Income towards Common Stockholders fell 40733.65% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year decrease of 2191.21%. This contributed to the annual value of -$3.8 million for FY2024, which is 30844.02% down from last year.
- According to the latest figures from Q3 2025, Eton Pharmaceuticals' Net Income towards Common Stockholders is -$1.9 million, which was down 40733.65% from -$2.6 million recorded in Q2 2025.
- Over the past 5 years, Eton Pharmaceuticals' Net Income towards Common Stockholders peaked at $5.1 million during Q1 2021, and registered a low of -$6.1 million during Q3 2021.
- Moreover, its 5-year median value for Net Income towards Common Stockholders was -$1.6 million (2025), whereas its average is -$1.1 million.
- In the last 5 years, Eton Pharmaceuticals' Net Income towards Common Stockholders soared by 39261.87% in 2023 and then crashed by 40733.65% in 2025.
- Eton Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at $1.0 million in 2021, then fell by 12.22% to $912000.0 in 2022, then plummeted by 347.37% to -$2.3 million in 2023, then skyrocketed by 73.49% to -$598000.0 in 2024, then crashed by 222.24% to -$1.9 million in 2025.
- Its last three reported values are -$1.9 million in Q3 2025, -$2.6 million for Q2 2025, and -$1.6 million during Q1 2025.